FAQ

BET Bromodomains 2/3/4 Inhibitor MK-8628

Known as: MK-8628 
A synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2016
024620162016

Related topics

Related topics

1 relation
OTX015

Related mentions per year

Related mentions per year

2015-2018
201020122014201620182020
BET Bromodomains 2/3/4 Inhibitor MK-8628
OTX015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subgroup of breast tumors clinically defined by the lack… (More)
Is this relevant?
2017
2017
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
The SCLC combination screen examined a 9-point concentration response of 180 third agents, alone and in combination with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
BACKGROUND The first-in-class small molecule inhibitor OTX015 (MK-8628) specifically binds to bromodomain motifs BRD2, BRD3, and… (More)
Is this relevant?
2016
2016
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Bromodomain and extraterminal (BET) bromodomain (BRD) proteins are epigenetic readers that bind to acetylated lysine residues on… (More)
  • figure 6
Is this relevant?
2016
2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
BACKGROUND Bromodomain and extraterminal (BET) proteins are chromatin readers that preferentially affect the transcription of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2016
2016
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
BACKGROUND AND OBJECTIVES OTX015 (MK-8628) is a novel inhibitor of the bromodomain and extraterminal (BET)-bromodomain (BRD… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
  • table 4
Is this relevant?
2016
2016
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Inhibitors targeting epigenetic control points of oncogenes offer a potential mean of blocking tumor progression in small cell… (More)
Is this relevant?
2016
2016
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
The bromodomain inhibitor OTX015 (MK-8628) has shown anti-lymphoma activity as a single agent in both the preclinical and… (More)
Is this relevant?